Literature DB >> 17608029

Drug evaluation: CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer.

Deepali Sachdev1.   

Abstract

Several phase II trials of CP-751871 are currently underway, including a phase Ib/II [corrected] trial of CP-751871 in combination with paclitaxel and carboplatin in patients with advanced NSCLC, a phase II trial of CP-751871 in combination with docetaxel and prednisone in patients with hormone-refractory prostate cancer, and a phase II trial of CP-751871 in combination with exemestane in hormone receptor positive advanced breast cancer [corrected]

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17608029

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  4 in total

Review 1.  Novel targeted therapeutics for metastatic castration-resistant prostate cancer.

Authors:  Emmanuel S Antonarakis; Michael A Carducci; Mario A Eisenberger
Journal:  Cancer Lett       Date:  2009-08-29       Impact factor: 8.679

Review 2.  Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.

Authors:  Quanri Jin; Francisco J Esteva
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-25       Impact factor: 2.673

3.  Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups.

Authors:  Sofie Björner; Ann H Rosendahl; Maria Simonsson; Andrea Markkula; Karin Jirström; Signe Borgquist; Carsten Rose; Christian Ingvar; Helena Jernström
Journal:  Oncotarget       Date:  2017-02-07

4.  Loss of neutrophil polarization in colon carcinoma liver metastases of mice with an inducible, liver-specific IGF-I deficiency.

Authors:  Roni F Rayes; Simon Milette; Maria Celia Fernandez; Boram Ham; Ni Wang; France Bourdeau; Stephanie Perrino; Shoshana Yakar; Pnina Brodt
Journal:  Oncotarget       Date:  2018-02-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.